The classic reference for psychotropic medications The Clinical Handbook of Psychotropic Drugs and the Clinical Handbook of Psychotropic Drugs for Children and Adolescents are independent and unbiased practical tools for psychiatrists, psychiatric nurses, pharmacists, psychologists, physicians, and all mental health professionals. They are packed with unique comparison charts that support effective medication decisions. Color-coding and instantly recognizable icons enable quick access to succinct, bulleted information on all classes of medication, their on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in special populations, nursing implications, and much more. Sections on Natural Health Products, Unapproved Treatments, ECT, BLT, and rTMS are included. Patient and caregiver information sheets are provided as printable PDF files New in this edition: • Neuroscience-based nomenclature – added to product availability tables • Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also updates to SSRI use in pregnancy and antidepressant augmentation strategies • Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment • Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised • New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection) • Breaking news: includes viloxazine (Qelbree), the first new drug for ADHD in children & adolescents approved by FDA in many years
|